Merck & Co annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Merck & Co Revenue Growth & History (MRK)
Merck & Co reported $65.01B in revenue for fiscal 2025, an increase of 1.31% from the previous fiscal year.
View full Merck & Co company overviewMerck & Co annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $65.01B | $843.0M | +1.31% |
| 2024 | 2024-12-31 | $64.17B | $4.05B | +6.74% |
| 2023 | 2023-12-31 | $60.12B | $832.0M | +1.40% |
| 2022 | 2022-12-31 | $59.28B | $10.58B | +21.72% |
| 2021 | 2021-12-31 | $48.70B | $7.19B | +17.31% |
| 2020 | 2020-12-31 | $41.52B | $2.40B | +6.13% |
| 2019 | 2019-12-31 | $39.12B | −$3.17B | −7.50% |
| 2018 | 2018-12-31 | $42.29B | $2.17B | +5.41% |
| 2017 | 2017-12-31 | $40.12B | $315.0M | +0.79% |
| 2016 | 2016-12-31 | $39.81B | $309.0M | +0.78% |
| 2015 | 2015-12-31 | $39.50B | −$2.74B | −6.48% |
| 2014 | 2014-12-31 | $42.24B | −$1.85B | −4.19% |
| 2013 | 2013-12-31 | $44.08B | −$3.18B | −6.74% |
| 2012 | 2012-12-31 | $47.27B | −$780.0M | −1.62% |
| 2011 | 2011-12-31 | $48.05B | $2.06B | +4.48% |
| 2010 | 2010-12-31 | $45.99B | $18.56B | +67.66% |
| 2009 | 2009-12-31 | $27.43B | $3.58B | +15.00% |
| 2008 | 2008-12-31 | $23.85B | −$347.7M | −1.44% |
| 2007 | 2007-12-31 | $24.20B | — | — |
Merck & Co quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.61B | $801.0M | +5.07% |
| Q1 2026 | 2026-03-31 | $16.29B | $757.0M | +4.87% |
| Q4 2025 | 2025-12-31 | $16.40B | $776.0M | +4.97% |
| Q3 2025 | 2025-09-30 | $17.28B | $619.0M | +3.72% |
| Q2 2025 | 2025-06-30 | $15.81B | −$306.0M | −1.90% |
| Q1 2025 | 2025-03-31 | $15.53B | −$246.0M | −1.56% |
| Q4 2024 | 2024-12-31 | $15.62B | $993.0M | +6.79% |
| Q3 2024 | 2024-09-30 | $16.66B | $695.0M | +4.35% |
| Q2 2024 | 2024-06-30 | $16.11B | $1.08B | +7.16% |
| Q1 2024 | 2024-03-31 | $15.78B | $1.29B | +8.89% |
| Q4 2023 | 2023-12-31 | $14.63B | $801.0M | +5.79% |
| Q3 2023 | 2023-09-30 | $15.96B | $1.00B | +6.70% |
| Q2 2023 | 2023-06-30 | $15.04B | $442.0M | +3.03% |
| Q1 2023 | 2023-03-31 | $14.49B | −$1.41B | −8.89% |
| Q4 2022 | 2022-12-31 | $13.83B | $309.0M | +2.29% |
| Q3 2022 | 2022-09-30 | $14.96B | $1.80B | +13.72% |
| Q2 2022 | 2022-06-30 | $14.59B | $3.19B | +27.99% |
| Q1 2022 | 2022-03-31 | $15.90B | $5.27B | +49.63% |
| Q4 2021 | 2021-12-31 | $13.52B | $4.34B | +47.30% |
| Q3 2021 | 2021-09-30 | $13.15B | $2.23B | +20.36% |
| Q2 2021 | 2021-06-30 | $11.40B | $2.05B | +21.91% |
| Q1 2021 | 2021-03-31 | $10.63B | −$1.43B | −11.86% |
| Q4 2020 | 2020-12-31 | $9.18B | $5.03B | +121.29% |
| Q3 2020 | 2020-09-30 | $10.93B | −$1.47B | −11.84% |
| Q2 2020 | 2020-06-30 | $9.35B | −$2.41B | −20.47% |
| Q1 2020 | 2020-03-31 | $12.06B | $1.24B | +11.47% |
| Q4 2019 | 2019-12-31 | $4.15B | −$6.85B | −62.28% |
| Q3 2019 | 2019-09-30 | $12.40B | $1.60B | +14.85% |
| Q2 2019 | 2019-06-30 | $11.76B | $1.29B | +12.37% |
| Q1 2019 | 2019-03-31 | $10.82B | $779.0M | +7.76% |
| Q4 2018 | 2018-12-31 | $11.00B | $565.0M | +5.42% |
| Q3 2018 | 2018-09-30 | $10.79B | $469.0M | +4.54% |
| Q2 2018 | 2018-06-30 | $10.46B | $535.0M | +5.39% |
| Q1 2018 | 2018-03-31 | $10.04B | $603.0M | +6.39% |
| Q4 2017 | 2017-12-31 | $10.43B | $318.0M | +3.14% |
| Q3 2017 | 2017-09-30 | $10.32B | −$211.0M | −2.00% |
| Q2 2017 | 2017-06-30 | $9.93B | $86.0M | +0.87% |
| Q1 2017 | 2017-03-31 | $9.43B | $122.0M | +1.31% |
| Q4 2016 | 2016-12-31 | $10.12B | −$100.0M | −0.98% |
| Q3 2016 | 2016-09-30 | $10.54B | $463.0M | +4.60% |
| Q2 2016 | 2016-06-30 | $9.84B | $59.0M | +0.60% |
| Q1 2016 | 2016-03-31 | $9.31B | −$113.0M | −1.20% |
| Q4 2015 | 2015-12-31 | $10.21B | −$267.0M | −2.55% |
| Q3 2015 | 2015-09-30 | $10.07B | −$484.0M | −4.58% |
| Q2 2015 | 2015-06-30 | $9.79B | −$1.15B | −10.51% |
| Q1 2015 | 2015-03-31 | $9.43B | −$839.0M | −8.17% |
| Q4 2014 | 2014-12-31 | $10.48B | −$888.0M | −7.81% |
| Q3 2014 | 2014-09-30 | $10.56B | −$475.0M | −4.31% |
| Q2 2014 | 2014-06-30 | $10.93B | −$76.0M | −0.69% |
| Q1 2014 | 2014-03-31 | $10.26B | −$407.0M | −3.81% |
| Q4 2013 | 2013-12-31 | $11.37B | −$367.0M | −3.13% |
| Q3 2013 | 2013-09-30 | $11.03B | −$456.0M | −3.97% |
| Q2 2013 | 2013-06-30 | $11.01B | −$1.30B | −10.57% |
| Q1 2013 | 2013-03-31 | $10.67B | −$1.06B | −9.04% |
| Q4 2012 | 2012-12-31 | $11.74B | −$557.0M | −4.53% |
| Q3 2012 | 2012-09-30 | $11.49B | −$534.0M | −4.44% |
| Q2 2012 | 2012-06-30 | $12.31B | $160.0M | +1.32% |
| Q1 2012 | 2012-03-31 | $11.73B | $151.0M | +1.30% |
| Q4 2011 | 2011-12-31 | $12.29B | $200.4M | +1.66% |
| Q3 2011 | 2011-09-30 | $12.02B | $897.1M | +8.06% |
| Q2 2011 | 2011-06-30 | $12.15B | $804.7M | +7.09% |
| Q1 2011 | 2011-03-31 | $11.58B | $157.8M | +1.38% |
| Q4 2010 | 2010-12-31 | $12.09B | $2.00B | +19.82% |
| Q3 2010 | 2010-09-30 | $11.12B | $5.08B | +83.89% |
| Q2 2010 | 2010-06-30 | $11.35B | $5.45B | +92.31% |
| Q1 2010 | 2010-03-31 | $11.42B | $6.04B | +112.10% |
| Q4 2009 | 2009-12-31 | $10.09B | — | — |
| Q3 2009 | 2009-09-30 | $6.05B | $1.47B | +32.20% |
| Q2 2009 | 2009-06-30 | $5.90B | $978.9M | +19.89% |
| Q1 2009 | 2009-03-31 | $5.39B | — | — |
| Q3 2008 | 2008-09-30 | $4.58B | — | — |
| Q2 2008 | 2008-06-30 | $4.92B | — | — |
Merck & Co revenue growth trends
Over the last five reported fiscal years, revenue grew from $41.52B to $65.01B, a compound annual growth rate of 9.38%. Merck & Co's latest reported quarter, Q2 2026, generated $16.61B in revenue, an increase of 5.07% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Merck & Co source filings ↗Community posts
Merck licenses preclinical cancer drug for $400 million upfront
Merck ($MRK) has completed an exclusive worldwide licensing agreement with SciBrunch Therapeutics for SPR2015, an experimental oral inhibitor targeting the active form of KRAS G12D. Merck gains development, manufacturing and commercializati ...
Merck wins FDA approval for Welireg–Lenvima kidney-cancer combination
Merck ($MRK) received FDA approval for Welireg plus Lenvima as an oral treatment for adults with advanced clear-cell renal cell carcinoma after a PD-1 or PD-L1 inhibitor. The decision adds a treatment option for patients whose kidney cancer ...
Merck’s Keytruda–Padcev regimen advances toward broader European use
Merck ($MRK) received a positive European advisory opinion for Keytruda combined with Padcev before and after radical cystectomy in adults with resectable muscle-invasive bladder cancer. The recommendation also covers subcutaneous Keytruda. ...
